# Q-linea

its ASTar system runs rapid phenotypic antibiotic susceptibility testing directly from positive blood culture, and the company recently announced FDA clearance of an expanded ASTar blood-testing menu, extending the platform's antibiotic and pathogen coverage.

Source: https://en.bioecon.ru/companies/q-linea/
Updated: 2026-07-20

- Country: Sweden

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Funding | SEK 312 million rights issue completed in November 2025 | https://qlinea.com/0986741_wp-uploads/2026/05/Qlinea_2025_ENG.pdf, https://qlinea.com/mfn_news/year-end-report-1-january-31-december-2025/ |
| Capacity | Internalized consumables production and antibiotic filling/drying process increased production capacity | https://qlinea.com/0986741_wp-uploads/2026/05/Qlinea_2025_ENG.pdf |
| Certification | CE-IVDR certification for ASTar instrument and consumables | https://qlinea.com/0986741_wp-uploads/2026/05/Qlinea_2025_ENG.pdf, https://storage.mfn.se/c3f795b4-c8ad-4188-9f3f-d6f4f952ceab/qlinea-2024-eng.pdf |
| Regulatory approval | FDA 510(k) clearance for ASTar system (April 2024) and expanded Gram-negative Blood Culture menu (April 2026) | https://qlinea.com/0986741_wp-uploads/2026/05/Qlinea_2025_ENG.pdf, https://qlinea.com/mfn_news/q-linea-announces-fda-clearance-of-expanded-astar-blood-testing-menu/, https://storage.mfn.se/c3f795b4-c8ad-4188-9f3f-d6f4f952ceab/qlinea-2024-eng.pdf |
| Production site | Consumables production premises on Palmbladsgatan, Uppsala, Sweden | https://qlinea.com/0986741_wp-uploads/2026/05/Qlinea_2025_ENG.pdf |
| Headcount | 70 employees as of June 30, 2026 | https://stockanalysis.com/quote/sto/QLINEA/employees/ |
| Revenue | 15.29M SEK for the full year 2025 | https://stockanalysis.com/quote/sto/QLINEA/revenue/ |

Independent sources: stockanalysis.com, storage.mfn.se

## Technologies

- [Rapid antibiotic-resistance tests](https://en.bioecon.ru/technology/rapid-antibiotic-resistance-tests/)